Johnson & Johnson (NYSE:JNJ) Stock Holdings Raised by Monograph Wealth Advisors LLC

Monograph Wealth Advisors LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 8.8% during the 4th quarter, HoldingsChannel.com reports. The firm owned 4,458 shares of the company’s stock after buying an additional 359 shares during the quarter. Monograph Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $645,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Sulzberger Capital Advisors Inc. bought a new position in Johnson & Johnson in the fourth quarter worth about $453,000. Oregon Pacific Wealth Management LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter worth about $949,000. Horan Securities Inc. grew its holdings in Johnson & Johnson by 1.3% in the 4th quarter. Horan Securities Inc. now owns 7,178 shares of the company’s stock worth $1,038,000 after buying an additional 90 shares in the last quarter. Strategic Financial Concepts LLC increased its holdings in shares of Johnson & Johnson by 57.9% during the fourth quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company’s stock valued at $501,000 after purchasing an additional 1,271 shares during the period. Finally, State of Wyoming raised its stake in shares of Johnson & Johnson by 205,580.0% during the fourth quarter. State of Wyoming now owns 10,284 shares of the company’s stock valued at $1,487,000 after purchasing an additional 10,279 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Morgan Stanley boosted their price target on shares of Johnson & Johnson from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 16th. Guggenheim restated a “neutral” rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Benchmark raised Johnson & Johnson to a “strong-buy” rating in a research note on Thursday, April 24th. Finally, Sanford C. Bernstein restated a “market perform” rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Eleven equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $170.88.

Johnson & Johnson Stock Up 0.7%

NYSE JNJ opened at $153.58 on Wednesday. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $369.52 billion, a price-to-earnings ratio of 23.09, a PEG ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The stock’s 50 day moving average is $155.87 and its two-hundred day moving average is $153.80.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.59 by $0.18. The firm had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be issued a $1.30 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.39%. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson’s dividend payout ratio is currently 57.84%.

Insider Buying and Selling

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the transaction, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. The trade was a 25.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.16% of the stock is owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.